Co-Diagnostics Statistics
Total Valuation
Co-Diagnostics has a market cap or net worth of $11.95 million. The enterprise value is -$15.72 million.
Important Dates
The next estimated earnings date is Thursday, May 8, 2025, after market close.
| Earnings Date | May 8, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
Co-Diagnostics has 33.57 million shares outstanding. The number of shares has increased by 3.37% in one year.
| Current Share Class | 33.57M |
| Shares Outstanding | 33.57M |
| Shares Change (YoY) | +3.37% |
| Shares Change (QoQ) | +1.25% |
| Owned by Insiders (%) | 6.60% |
| Owned by Institutions (%) | 17.21% |
| Float | 31.36M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 2.74 |
| Forward PS | 7.51 |
| PB Ratio | 0.22 |
| P/TBV Ratio | 0.42 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 4.41, with a Debt / Equity ratio of 0.04.
| Current Ratio | 4.41 |
| Quick Ratio | 4.08 |
| Debt / Equity | 0.04 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -53.65% and return on invested capital (ROIC) is -34.44%.
| Return on Equity (ROE) | -53.65% |
| Return on Assets (ROA) | -31.45% |
| Return on Invested Capital (ROIC) | -34.44% |
| Return on Capital Employed (ROCE) | -70.71% |
| Revenue Per Employee | $29,660 |
| Profits Per Employee | -$285,144 |
| Employee Count | 132 |
| Asset Turnover | 0.05 |
| Inventory Turnover | 0.73 |
Taxes
In the past 12 months, Co-Diagnostics has paid $57,368 in taxes.
| Income Tax | 57,368 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -69.04% in the last 52 weeks. The beta is 1.21, so Co-Diagnostics's price volatility has been higher than the market average.
| Beta (5Y) | 1.21 |
| 52-Week Price Change | -69.04% |
| 50-Day Moving Average | 0.47 |
| 200-Day Moving Average | 0.94 |
| Relative Strength Index (RSI) | 42.86 |
| Average Volume (20 Days) | 202,568 |
Short Selling Information
The latest short interest is 162,551, so 0.48% of the outstanding shares have been sold short.
| Short Interest | 162,551 |
| Short Previous Month | 202,412 |
| Short % of Shares Out | 0.48% |
| Short % of Float | 0.52% |
| Short Ratio (days to cover) | 0.63 |
Income Statement
In the last 12 months, Co-Diagnostics had revenue of $3.92 million and -$37.64 million in losses. Loss per share was -$1.24.
| Revenue | 3.92M |
| Gross Profit | 2.92M |
| Operating Income | -40.08M |
| Pretax Income | -35.81M |
| Net Income | -37.64M |
| EBITDA | -38.70M |
| EBIT | -40.08M |
| Loss Per Share | -$1.24 |
Full Income StatementBalance Sheet
The company has $29.75 million in cash and $2.15 million in debt, giving a net cash position of $27.60 million or $0.82 per share.
| Cash & Cash Equivalents | 29.75M |
| Total Debt | 2.15M |
| Net Cash | 27.60M |
| Net Cash Per Share | $0.82 |
| Equity (Book Value) | 54.31M |
| Book Value Per Share | 1.64 |
| Working Capital | 24.98M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$29.16 million and capital expenditures -$748,352, giving a free cash flow of -$29.90 million.
| Operating Cash Flow | -29.16M |
| Capital Expenditures | -748,352 |
| Free Cash Flow | -29.90M |
| FCF Per Share | -$0.89 |
Full Cash Flow StatementMargins
| Gross Margin | 74.48% |
| Operating Margin | -1,023.75% |
| Pretax Margin | -959.90% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Co-Diagnostics does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -3.37% |
| Shareholder Yield | -3.37% |
| Earnings Yield | -316.88% |
| FCF Yield | -251.75% |
Analyst Forecast
The average price target for Co-Diagnostics is $1.00, which is 180.90% higher than the current price. The consensus rating is "Hold".
| Price Target | $1.00 |
| Price Target Difference | 180.90% |
| Analyst Consensus | Hold |
| Analyst Count | 1 |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsStock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Co-Diagnostics has an Altman Z-Score of 0.05 and a Piotroski F-Score of 2. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 0.05 |
| Piotroski F-Score | 2 |